Incretin Based Drugs Market
Global Incretin Based Drugs Market Size, Share & Trends Analysis Report by Drug Type (Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors), by Route of Administration (Oral and Injectable), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast (2022-2028)
The global incretin-based drugs market is anticipated to grow at a significant CAGR of 5.5% during the forecast period. When carbohydrates are consumed, blood sugar may be excessively high after a meal if a person has type-2 diabetes. The glucagon levels of people suffering from type-2 diabetes remain excessively high post-meals. incretin-based drugs suppress post-meal glucagon and decrease post-meal blood glucose levels. These drugs also keep blood sugar levels in check. Thus, the rising prevalence of obesity and diabetes are major factors contributing towards the growth of the market. For instance, in 2019, the British Diabetic Association estimated that around 3.7 million people in the UK have been diagnosed with diabetes, the number is increased two times over the decade. Furthermore, 12.3 million people in the UK are at risk of developing type-2 diabetes.
Impact of COVID-19 Pandemic on Global Incretin Based Drugs Market
The COVID-19 pandemic had impacted the global incretin industry significantly owning to the lockdown in most of the nations to control the spread of the virus. It affected the overall demand for incretin-based drugs in the market. Covid-19 situation produced economic instability as the outbreak forced both manufacturing and service industries to close for extended periods of time and focus was shifted to the covid essential manufacturing.
Segmental Outlook
The global incretin-based drugs market is segmented based on drug type, route of administration and distribution channel. Based on the drug type, the market is sub-segmented into glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Based on the route of administration, the market is sub-segmented into the oral and injectable. Based on distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies and online pharmacies. Among these, the glucagon-like peptide-1 receptor agonists is expected to hold prominent share among the incretin-based market.
Global Incretin based drugs Market Share by Distribution Channel, 2021 (%)
Hospital Pharmacies is Anticipated to Cater Considerable CAGR of the Global Incretin Based Drugs Market
Among the distribution channel, the hospital pharmacies are anticipated to grow significantly over the forecast period, owing to the limited availability of the incretin-based drugs in other retail pharmacies globally. The incretin-based drugs are prescribed to people diagnosed with extreme symptoms of type-2 diabetes, thus are rarely prescribed and are not easily available. Incretins are hormones that are released from the gut into the bloodstream in response to ingestion of food, and they then modulate the insulin secretory response to the products within the nutrients in the food. Hence, rarely available in across the market. However, various alternatives of incretin-based drugs such as metformin, which are easily available among the retail and online pharmacies. Such types of alternatives are also being prescribed and used to treat acute diabetes, due to less availability of incretin-based drug.
Regional Outlooks
The global incretin based drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific anticipated to hold significant share in the market followed by North America, and then Europe.
Global Incretin based drugs Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Incretin Based Drugs Market
During the forecast period, Asia-Pacific is expected to grow at a considerable CAGR due to increasing incidence of diabetes and geriatric & obese population across the nations such as China and India, among others. According to the World Health Organization, in November 2021, diabetes is becoming more common in middle and low-income nations, and diabetes is becoming more common among adults over the age of 18. Furthermore, other factors driving the growth of developing drugs and medicines for diabetes is the growing funding activities for diabetes control by the government of the countries. For instance, the Indian Government is running a campaign to raise diabetes awareness, developing understanding of injectable drug delivery systems, and transitioning from traditional injection to ready-to-use injectable.
Market Players Outlook
The major companies serving the global incretin-based drugs market include AstraZeneca, Boehringer Ingelheim International GmnH, Eli Lilly and Co., GlaxosmithKline plc., Merck & Co. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2018, Eli Lilly initiated its phase 2 clinical trial of dual GIP and GLP-1 receptor agonist. The trials had shown tremendous reduction in blood sugar level and weight loss in people suffering with type-2 diabetes.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global incretin-based drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Incretin Based Drugs Market
- Recovery Scenario of Global Incretin Based Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AstraZeneca
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Boehringer Ingelheim International GmbH
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Eli Lilly and Co.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. GlaxoSmithKline plc.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Merck & Co.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Incretin based drugs Market by Drug Type
4.1.1. Glucagon-like Peptide-1 (GLP-) Receptor Agonists
4.1.2. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
4.2. Global Incretin based drugs Market by Route of Administration
4.2.1. Oral
4.2.2. Injectable
4.3. Global Incretin based drugs Market by Distribution Channel
4.3.1. Hospital Pharmacies
4.3.2. Retail Pharmacies
4.3.3. Online Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Novartis AG
6.2. Sanofi SA
6.3. Novo Nordisk A/S
6.4. Johnson & Johnson Pvt. Ltd.
6.5. TAKEDA Pharmaceutical Co. Ltd.
6.6. Bayer AG
6.7. Cadila Pharmaceuticals
6.8. USV Pvt. Ltd.
6.9. Sun Pharmaceutical Industries Ltd.
6.10. Biocon
6.11. Glenmark
1. GLOBAL INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
5. GLOBAL ORAL INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL INJECTABLE INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
8. GLOBAL INCRETIN BASED DRUGS IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL INCRETIN BASED DRUGS IN RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL INCRETIN BASED DRUGS IN ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
15. NORTH AMERICAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
16. EUROPEAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
18. EUROPEAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
19. EUROPEAN INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
24. REST OF THE WORLD INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. REST OF THE WORLD INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
26. REST OF THE WORLD INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
27. REST OF THE WORLD INCRETIN BASED DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL INCRETIN BASED DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL INCRETIN BASED DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL INCRETIN BASED DRUGS MARKET, 2022-2028 (%)
4. GLOBAL INCRETIN BASED DRUGS MARKET SHARE BY DRUG TYPE, 2021 VS 2028 (%)
5. GLOBAL GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS INCRETIN BASED DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR INCRETIN BASED DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL INCRETIN BASED DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
8. GLOBAL ORAL INCRETIN BASED DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL INJECTABLE INCRETIN BASED DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL INCRETIN BASED DRUGS MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
11. GLOBAL INCRETIN BASED DRUGS IN HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL INCRETIN BASED DRUGS IN RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL INCRETIN BASED DRUGS IN ONLINE PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL INCRETIN BASED DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. UK INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD INCRETIN BASED DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
